Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China To Tighten Control Over Stimulants

This article was originally published in PharmAsia News

Executive Summary

In China's continuous crack down on illegal production and trading of stimulants, China's State FDA, State Administration for Industry & Commerce, Ministry of Industry & Information Technology and Ministry of Public Security have jointly announced that effective June 19, all chemical companies should not produce or deal with prohibited substances in the catalog of stimulants without permission. Online advertising and sales of such products, including protein assimilation preparations and peptide hormones, are also strictly prohibited. China will further intensify inspection work: eight ministries including the Ministry of Health and SFDA will inspect the stimulant management of the six Olympics host cities from late June to early July; investigation and confirmation of contraband will lead to heavy prosecution; and telephone number and email address will be publicized for informants. (Click here for more - Chinese Language)

You may also be interested in...



Deal Watch: Lilly Finds New Partners For Genetic Disorders, Protein Degradation

Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.

How Merck Plans To Protect Commercial Info Under EU Clinical Trial Rules

In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.

UK Supplements Marketer Makes No Effort To Back Up Ad Claims

The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel